Description Synthesis Precautions References
ChemicalBook > CAS DataBase List > Tolvaptan

Tolvaptan

Description Synthesis Precautions References
Product Name
Tolvaptan
CAS No.
150683-30-0
Chemical Name
Tolvaptan
Synonyms
SaMsca;Tolvptan;olvaptan;Toptan *;OPC-41061;OPC 41061;Tolvaptan;TOIVAPTAN;Tolvaptan-d7;Tolvaptan powder
CBNumber
CB41454279
Molecular Formula
C26H25ClN2O3
Formula Weight
448.94
MOL File
150683-30-0.mol
More
Less

Tolvaptan Property

Melting point:
219-222°C
Boiling point:
594.4±50.0 °C(Predicted)
Density 
1.311±0.06 g/cm3(Predicted)
storage temp. 
2-8°C
solubility 
DMSO: ≥15mg/mL
pka
13.00±0.70(Predicted)
form 
powder
color 
white to tan
InChI
InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)
InChIKey
GYHCTFXIZSNGJT-UHFFFAOYSA-N
SMILES
C(NC1=CC=C(C(N2C3=CC=C(Cl)C=C3C(O)CCC2)=O)C(C)=C1)(=O)C1=CC=CC=C1C
More
Less

Safety

WGK Germany 
3
Hazardous Substances Data
150683-30-0(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H361Suspected of damaging fertility or the unborn child

H362May cause harm to breast-fed children

Precautionary statements

P201Obtain special instructions before use.

P202Do not handle until all safety precautions have been read and understood.

P260Do not breathe dust/fume/gas/mist/vapours/spray.

P263Avoid contact during pregnancy/while nursing.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P281Use personal protective equipment as required.

P308+P313IF exposed or concerned: Get medical advice/attention.

P405Store locked up.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
T7455
Product name
Tolvaptan
Purity
≥98% (HPLC), powder
Packaging
5mg
Price
$119
Updated
2024/03/01
Sigma-Aldrich
Product number
T7455
Product name
Tolvaptan
Purity
≥98% (HPLC), powder
Packaging
25mg
Price
$305.4
Updated
2024/03/01
Cayman Chemical
Product number
19691
Product name
Tolvaptan
Purity
≥98%
Packaging
1mg
Price
$32
Updated
2024/03/01
Cayman Chemical
Product number
19691
Product name
Tolvaptan
Purity
≥98%
Packaging
5mg
Price
$86
Updated
2024/03/01
Cayman Chemical
Product number
19691
Product name
Tolvaptan
Purity
≥98%
Packaging
10mg
Price
$153
Updated
2024/03/01
More
Less

Tolvaptan Chemical Properties,Usage,Production

Description

Tolvaptan(trade names Samsca and Jinarc) is an oral selective vasopressin antagonist developed by Otsuka for the treatment of hyponatremia, and it is a non-peptide selective antidiuretic hormone receptor antagonist. The drug can increase the concentration of sodium ions in the plasma, and help the excess water discharge from the urine. The drug could enhance the ability of the kidney to deal with water, and significantly reduce the weight and edema of patients while not accompanied by increased electrolyte excretion, without destroying the blood electrolyte balance. The drug can be used to treat hyponatremia caused by congestive heart failure, various edematous diseases, cirrhosis and antidiuretic hormone deficiency syndrome. The study found that, when the plasma sodium concentration decreased, in order to maintain the balance of sodium concentration inside and outside the cell, extracellular fluid will enter the cell, so the cells will swell. When the brain cells swell, it will lead to a variety of hyponatremia symptoms, including dizziness, weakness, headache, nausea, confusion, consciousness and convulsions. Severe hyponatremia can lead to coma and death. There is no corresponding study of tolvaptan tablets in patients with severe hyponatremia.

Synthesis


Fugure 1: Synthesis of Tolvaptan

Precautions

Tolvaptan(SAMSCA) should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely. Too rapid correction of hyponatremia (e.g., >12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death. In susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable.
Tolvaptan(SAMSCA) is contraindicated in the following conditions:

  • Urgent need to raise serum sodium acutely
  • Inability of the patient to sense or appropriately respond to thirst
  • Hypovolemic hyponatremia
  • Concomitant use of strong CYP 3A inhibitors
  • Anuric patients
  • Hypersensitivity (e.g. anaphylactic shock, rash generalized) to tolvaptan or its components

References

https://www.samsca.com/dosing-and-administration
https://en.wikipedia.org/wiki/Tolvaptan

Description

The potent antidiuretic hormone AVP orchestrates the regulation of free water absorption, body fluid osmolality, cell contraction, blood volume, and blood pressure through stimulation of three G-proteincoupled receptor subtypes:V1-vascular types a and b, V2-renal, and V3-pituitary. Increased AVP secretion is the trademark of several pathophysiological disorders, including heart failure, impaired renal function, liver cirrhosis, and SIADH. As a consequence, these patients experience excess water retention or inadequate free-water excretion, which results in the dilution of sodium concentrations, frequently manifesting as clinical hyponatremia (serum sodium concentration <135 mmol/L). This electrolyte imbalance increases mortality rates by 60-fold. Selective antagonism of the AVP V2receptor promotes water excretion without perturbing electrolyte balance making it an appealing target for preventing disease progression. Following the introduction of the dual AVP V1a/V2 receptor antagonist conivaptan, tolvaptan has recently been launched as a nonpeptide, selective V2 receptor antagonist with potent aquaretic attributes for the treatment of hypervolemic and euvolemic hyponatremia (serum sodium concentration of <125 mmol/L or less distinct hyponatremia that is symptomatic and has resisted correction with fluid restriction). As a more potent and selective V2 receptor antagonist, tolvaptan is a follow-up to mozavaptan, which possesses weak V1 receptor antagonism and was approved for the treatment of SIADH in Japan. .

Description

Tolvaptan is a nonpeptide vasopressin V2 receptor antagonist (IC50 = 3 nM for rat receptor) and a diuretic agent. It is selective for V2 over V1 receptors (IC50 = 0.58 μM). Tolvaptan increases urine volume by 3-fold in rats when administered at a dose of 0.54 mg/kg. It also reduces left ventricular end-systolic volumes and improves left ventricular ejection fraction in a rat model of myocardial infarction. Formulations containing tolvaptan have been used to treat hyponatremia.

Chemical Properties

White Solid

Originator

Otsuka Pharmaceutical (US)

Uses

Tolvaptan (OPC-41061) is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28μM for the inhibition of AVP-induced platelet aggregation. Tolvaptan (OPC-41061) is used to treat hyponatremia (low blood sodium levels) assoc

Uses

Labelled Tolvaptan s, and the syndrome of inappropriate antidiuretic hormone (SIADH).

Uses

It is a selective, competitive arginine vasopressin V2 receptor antagonist f inappropriate antidiuretic hormone (SIADH).

Definition

ChEBI: Tolvaptan is a benzazepine derivative incorporating a benzenedicarboxamide function whch is a selective vasopressin V2 receptor antagonist used to treat euvolemic and hypervolemic hyponatremia. It is also used in the treatment of rapidly progressing autosomal dominant polycystic kidney disease to slow the rate of cyst development and renal insufficiency. Tolvaptan is a racemate consisting of a 1:1 mixture of 5R and 5S stereomers. It has a role as a vasopressin receptor antagonist. It is a benzazepine and a benzenedicarboxamide.

brand name

Samsca

Biochem/physiol Actions

Tolvaptan (OPC 41061) is a potent, orally active non-peptide vasopressin V2 selective antagonist. IC50 = 3 nM at the rat V2 receptor; 29 times more selective for the V2 than for V1a. Tolvaptan has also been shown to inhibit the development of polycystic kidney disease in several animal models.

Clinical Use

Tolvaptan, also known as OPC-41061, is a selective, competitive arginine vasopressin receptor 2 antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). Otsuka Pharmaceutical licensed tolvaptan under the trade name Samsca after the FDA approved the drug in May 2009. Tolvaptan has also shown efficacy against polycystic kidney disease. In a 2004 trial, tolvaptan administered with traditional diuretics was noted to increase excretion of excess fluids and improve blood sodium levels in patients with heart failure without producing side effects such as hypotension (low blood pressure) or hypokalemia (decreased blood levels of potassium). The drug also exhibited no adverse effect on kidney function.

Side effects

The most common adverse events were thirst, dry mouth, asthenia, constipation, pollakiuria or polyuria, and hyperglycemia. The recommended starting dose is 15 mg daily with a daily 15-mg adjustment to a maximum of 60 mg daily to raise serum sodium concentration. Initiation should be in a hospital setting where serum sodium and volume status may be monitored since too rapid correction of hyponatremia (>12 mEq/L/24 h) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, spastic quadriparesis, seizures, coma, and death. In addition to avoiding concomitant use of strong CYP3A4 inhibitors, tolvaptan is contraindicated in settings of urgent need to raise serum sodium acutely, in patients with an inability to sense or appropriately respond to thirst, in hypovolemic hyponatremia conditions, and in anuric patients.

Synthesis

Tolvaptan may be prepared in 11 steps starting from 5chloro- 2-nitrobenzoic acid. Following esterification, reduction of the nitro moiety with tin(II) chloride, subsequent protection (tosylation) and alkylation of the resulting aniline, and a Dieckmann cyclization with potassium tert-butoxide generate the benzazepinone core that is ultimately decarboxylated by heating with hydrochloric acid in acetic acid. After deprotection of the amine group, condensation with 2methyl- 4-nitrobenzoyl chloride affords another nitro handle that is reduced with tin(II) chloride. This aniline is coupled with 2-methylbenzoyl chloride to give the penultimate intermediate. In the final step, reduction of the ketone functionality with sodium borohydride provides racemic tolvaptan that is formulated into 15- and 30-mg tablets for oral administration.

storage

Store at +4°C

References

[1] miyazaki t, fujiki h, yamamura y, et al. tolvaptan, an orally active vasopressin v2-receptor antagonist-pharmacology and

Tolvaptan Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Tolvaptan Suppliers

Brazil 1 Canada 4 China 269 Germany 2 India 40 Japan 2 South Korea 3 Spain 1 Switzerland 1 The Netherlands 1 United Kingdom 7 United States 27 Global 358
LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
MedChemexpress LLC
Tel
021-58955995
Fax
609-228-5909
Email
sales@medchemexpress.cn
Country
United States
ProdList
4861
Advantage
58
HBCChem, Inc.
Tel
+1-510-219-6317
Fax
+1-650-486-1361
Email
sales@hbcchem.com
Country
United States
ProdList
10648
Advantage
60
EMMX Biotechnology LLC
Tel
888-539-0666
Fax
888-539-0666
Email
info@emmx.com
Country
United States
ProdList
8447
Advantage
60
Target molecule Corp.
Tel
857-239-0968
Fax
857-239-8801
Email
service1@targetmol.com
Country
United States
ProdList
2559
Advantage
60
TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Country
United States
ProdList
32161
Advantage
58
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
Alchem Pharmtech,Inc.
Tel
8485655694
Email
sales@alchempharmtech.com
Country
United States
ProdList
63687
Advantage
58
Aladdin Scientific
Tel
+1-+1(833)-552-7181
Email
sales@aladdinsci.com
Country
United States
ProdList
57505
Advantage
58
Protheragen-ING
Tel
+16313385890
Email
info@protheragen-ing.com
Country
United States
ProdList
3868
Advantage
58
ApexBio Technology
Tel
--
Fax
--
Email
sales@apexbt.com
Country
United States
ProdList
6251
Advantage
58
Cayman Chemical Company
Tel
--
Fax
--
Email
cayman@caymanchem.com
Country
United States
ProdList
6213
Advantage
81
TOPCHEM PHARMACEUTICALS LTD
Tel
--
Fax
--
Email
Vinchem@vinchem.com
Country
United States
ProdList
140
Advantage
58
Selleck Chemicals LLC
Tel
--
Fax
--
Email
sales@selleckchem.com
Country
United States
ProdList
1848
Advantage
58
Oakwood Products, Inc.
Tel
--
Fax
--
Email
sales@oakwoodchemical.com
Country
United States
ProdList
6193
Advantage
74
PlusPharma Incorporated
Tel
--
Fax
--
Email
info@pluspharm.com
Country
United States
ProdList
53
Advantage
58
OChem Incorporation
Tel
--
Fax
--
Email
sales@ocheminc.com
Country
United States
ProdList
6501
Advantage
60
ACIC Fine Chemicals Inc.
Tel
--
Fax
--
Email
sales@acic.com
Country
United States
ProdList
492
Advantage
48
United States Biological
Tel
--
Fax
--
Email
chemicals@usbio.net
Country
United States
ProdList
6214
Advantage
80
MedChemExpress
Tel
--
Fax
--
Email
sales@medchemexpress.com
Country
United States
ProdList
6398
Advantage
58
AURORE LIFE SCIENCES PRIVATE LTD
Tel
--
Fax
--
Email
service@auroralifescience.com
Country
United States
ProdList
20
Advantage
58
Combi-Blocks Inc.
Tel
--
Fax
--
Email
sales@combi-blocks.com
Country
United States
ProdList
6618
Advantage
69
Riedel-de Haen AG
Tel
--
Fax
--
Country
United States
ProdList
6773
Advantage
87
Matrix Scientific
Tel
--
Fax
--
Email
sales@matrixscientific.com
Country
United States
ProdList
6632
Advantage
80
Tecoland Corporation
Tel
--
Fax
--
Email
info@tecoland.com
Country
United States
ProdList
275
Advantage
50
Santa Cruz Biotechnology, Inc.
Tel
--
Fax
--
Email
scbt@scbt.com
Country
United States
ProdList
3597
Advantage
60
LKT Laboratories, Inc.
Tel
--
Fax
--
Email
info@lktlabs.com
Country
United States
ProdList
2164
Advantage
64
More
Less

View Lastest Price from Tolvaptan manufacturers

Enki Biopharmaceuticals (Shanghai) Limited
Product
Tolvaptan 150683-30-0
Price
US $0.00-0.00/kg
Min. Order
1kg
Purity
99.5%
Supply Ability
5000
Release date
2023-11-26
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
Product
to Lvaptan 150683-30-0
Price
US $0.00/g
Min. Order
1g
Purity
More Than 99%
Supply Ability
100kg/Month
Release date
2024-11-15
Baoji Guokang Bio-Technology Co., Ltd.
Product
Tolvaptan 150683-30-0
Price
US $6563.00/KG
Min. Order
1KG
Purity
99%
Supply Ability
100kg
Release date
2021-06-07

150683-30-0, TolvaptanRelated Search:

Tofogliflozin Calcium levofolinate Calcitonin salmon Rivaroxaban BNP-32 (HUMAN) Sorafenib Torasemide Memantine Gemcitabine hydrochloride Ivabradine Simendan PD153035 HCl Dasatinib HO-3867 Sunitinib Malate ABT 263 Olaparib Toltrazuril

  • N-[4-(9-chloro-6-hydroxy-2-azabicyclo[5.4.0]undeca-8,10,12-triene-2-carbonyl)-3-methyl-phenyl]-2-methyl-benzamide
  • Tolvaptan
  • N-[4-[(5R)-7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl]-3-methylphenyl]-2-methylbenzamide
  • N-(4-{[(5R)-7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl}-3-Methylphenyl)-2-MethylbenzaMide
  • OPC 41061
  • OPC-41061
  • SaMsca
  • Tolvaptan Tablets
  • N-(4-(7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl)-3-Methylphenyl)-2-MethylbenzaMide
  • TOIVAPTAN
  • Tolvaptan-d7
  • N-(4-(7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-benzo[b]-azepine-1-carbonyl)-3-methylphenyl)-2-met
  • pazopanib hydrochloeide
  • N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methyl-benzamide
  • Tolvptan
  • (R)-N-(4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl)-3-methylphenyl)-2-methylbenzamide
  • N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide
  • Best Price Tolvaptan from China CAS NO.150683-30-0
  • Tolvaptan CAS NO.150683-30-0
  • High quality Cas: 150683-30-0 Tolvaptan powder
  • N-(4-(7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-benzo[b]-azepine-1-carbonyl)-3-methylphenyl)-2-
  • N-{4-[(5RS)-7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl]-3-methylphenyl}-2-methylbenzamide
  • Tolvaptan powder
  • tolvaptan manufactur
  • olvaptan
  • Benzamide, N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methyl-
  • Tolvaptan USP/EP/BP
  • Tolvaptan (OPC-41061)
  • TolvaptanQ: What is Tolvaptan Q: What is the CAS Number of Tolvaptan Q: What is the storage condition of Tolvaptan Q: What are the applications of Tolvaptan
  • (+-)-4'-((7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl) carbonyl)-o-tolu-m-toluidide
  • 1H-1-Benzazepine,benzamide deriv.
  • 7-Chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine
  • Toptan *
  • N,N'-Bis[4-(7-chloro-5-oxo-2,3,4,5-tetrahydro-1-benzoazepoxide-1-formyl)-3-methylphenyl]-oxamide
  • Tovaptan impurity Z
  • 150683-30-0
  • 83-30-0
  • C26H25ClN2O3
  • C26H18D7ClN2O3
  • 44894
  • Inhibitors
  • Samsca
  • Tolvaptan
  • Other APIs
  • APIs
  • Aromatics
  • Heterocycles
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Isotope Labelled Compounds
  • 150683-30-0
  • API